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Abstract 1 
Cardiomyopathies are complex heart muscle diseases that can be inherited or acquired. Dilated 2 
cardiomyopathy can result from mutations in LMNA, encoding the nuclear intermediate filament 3 
proteins lamin A/C. Some LMNA mutations lead to accumulation of the lamin A precursor, prelamin 4 
A, which is disease causing in a number of tissues yet its impact upon the heart is unknown. Here we 5 
discovered myocardial prelamin A accumulation occurred in a case of dilated cardiomyopathy and 6 
show that a novel mouse model of cardiac specific prelamin A accumulation exhibited a phenotype 7 
consistent with ‘inflammatory cardiomyopathy’ which we observed to be similar to HIV associated 8 
cardiomyopathy, an acquired disease state. Numerous HIV protease therapies are known to inhibit 9 
ZMPSTE24, the enzyme responsible for prelamin A processing, and we confirmed that accumulation 10 
of prelamin A occurred in HIV+ patient cardiac biopsies. These findings: (1) confirm a unifying 11 
pathological role for prelamin A common to genetic and acquired cardiomyopathies; (2) have 12 
implications for the management of HIV patients with cardiac disease suggesting protease inhibitors 13 
should be replaced with alternative therapies i.e. non-nucleoside reverse transcriptase inhibitors; and 14 
(3) suggest that targeting inflammation may be a useful treatment strategy for certain forms of 15 
inherited cardiomyopathy. 16 
Key words: Heart Failure, Cardiomyopathy, HIV, Prelamin A, Inflammation, Senescence. 17 
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Introduction 1 
Mutations in the LMNA gene are commonly implicated in dilated cardiomyopathy (DCM) phenotypes 2 
(1), accounting for approximately 6% of all cases (2). Investigation of in vivo mouse models 3 
harbouring LMNA mutations associated with clinical DCM have identified a number of  mechanisms 4 
associated with disease (3). However, some questions remain unresolved, in particular, whether the 5 
lamin A precursor, prelamin A is involved in the pathogenesis of cardiomyopathies (4-7). 6 
The LMNA gene produces two distinct proteins, lamin A and lamin C, which together with the 7 
B-type lamins form the nuclear lamina which sits adjacent to the inner nuclear membrane (INM) of 8 
the nuclear envelope (NE), on the nucleoplasmic side (8). The primary role of the lamina is to provide 9 
structural stability to the nuclear environment and to anchor heterochromatin, thereby facilitating 10 
appropriate gene expression and efficient DNA damage repair (9, 10). Additionally, the lamina forms 11 
part of the linker of nucleoskeleton to cytoskeleton (LINC) complex, which mediates physical 12 
communication with the cytoplasmic environment enabling rapid responses to physical cues, a 13 
process termed mechanotransduction (11). 14 
To achieve lamin A maturation, its precursor prelamin A, requires step-wise proteolytic 15 
processing (12). After translation, addition of farnesyl and carboxymethyl groups to a CAAX motif in 16 
the C terminus occurs, followed by an upstream cleavage exclusively mediated by zinc 17 
metalloproteinase STE24 homologue, ZMPSTE24, to yield mature lamin A (13-16). Retention of this 18 
farnesylated C terminal domain by lamin A precursors is pathologic and mutations in both the LMNA 19 
and ZMPSTE24 genes that cause this retention are implicated in premature ageing disorders, such as 20 
Hutchinson Gilford progeria syndrome (HGPS), as well as DCM. HGPS patients develop 21 
cardiomegaly, atrial enlargement and age-dependent diastolic and systolic dysfunction and left 22 
ventricle (LV) hypertrophy (17-19), while the DCM causing mutation LMNA-R89L has been shown 23 
to result in aberrant processing and accumulation of prelamin A (5, 7). Moreover, a mutation in 24 
LMNA postulated to inhibit prelamin A processing which causes Dunnigan-type familial 25 
lipodystrophy, is also associated with cardiac dysfunction, with patients homozygous for this mutation 26 
having worse left ventricle (LV) function indicating a dose-dependent effect (4). Additionally a 27 
 4 
mutation in ZMPSTE24 known to confer a reduction in enzyme activity was found in a patient with 1 
metabolic syndrome and cardiomyopathy (6). 2 
Another cause of prelamin A accumulation is via the pharmacological inhibition of 3 
ZMPSTE24 activity by Human Immunodeficiency Virus Protease Inhibitors (HIV PIs) used in the 4 
treatment of HIV. HIV PIs result in prelamin A accumulation in cells and potentially contribute to 5 
adverse effects (20, 21). HIV patients have double the risk for developing cardiovascular disease than 6 
non-carriers (22). Moreover, HIV patients can develop HIV-associated cardiomyopathy (23), though 7 
the aetiology is complex (24). Previous studies have identified nucleoside reverse transcriptase 8 
inhibitors (NRTIs) used in conjunction with HIV PIs as responsible for the development of 9 
cardiomyopathy in HIV patients (25, 26). Presently, there is limited knowledge on the impact of HIV 10 
PIs on the development of cardiomyopathy though there is an attempt to ‘characterise heart function 11 
on antiretroviral therapy’ with the introduction of the CHART study (27). These points considered, 12 
we sought to investigate the extent and effects of prelamin A accumulation in the setting of 13 
cardiomyopathy. 14 
Results 15 
Prelamin A can accumulate in DCM patient myocardium 16 
Immunofluorescence staining for prelamin A was performed on human DCM patient LV samples 17 
(Supp. Table 1) and non-failing (NF) control samples (Supp. Table 2), and quantified (Fig. 1A,B). 18 
Sporadic and focal expression of prelamin A was observable in cardiomyocyte (CM) nuclei in both 19 
non-failing and DCM samples. However, in one DCM sample (DCM05) consistent CM nuclear rim 20 
staining was found in 71.5% of total CM nuclei. Unfortunately there was no remaining tissue to 21 
perform Western blotting on the sample expressing prelamin A, however Western blotting blotting of 22 
a selection of the same samples supported the findings that generally prelamin A was not abundant 23 
across NF or DCM samples (Fig 1C).  24 
 25 
 5 
Prelamin A accumulation in cardiomyocytes of mice causes cardiomyopathy and premature 1 
death by heart failure 2 
To examine the effects of prelamin A on the heart cardiomyocyte specific prelamin A transgenic 3 
(csPLA-Tg) mice were generated.  csPLA-Tg mice (Fig. 2A) were born in a normal Mendelian ratio 4 
and were indistinguishable from floxed control (FLctrl) mice at birth. Western blotting confirmed that 5 
accumulation of prelamin A in csPLA-Tg mice was specific to the heart (Fig. 2B) and 6 
immunofluorescence showed that this occurred specifically in the nuclear rim of CMs (Fig. 2C). 7 
After weaning (day 21) csPLA-Tg mice ceased to grow and died prematurely. By 32 days, 8 
body weight was significantly lower in csPLA-Tg mice (Fig. 2D) and median survival was 9 
significantly attenuated in male and female mice compared with FLctrl (Fig. 2E).  10 
At two weeks csPLA-Tg mice showed no change in structural, dimensional or functional 11 
parameters by echocardiography as compared to FLctrl controls (Fig. 3A). In contrast, 12 
echocardiographic and MRI analysis of four-week mice showed that there was significant chamber 13 
dilatation as evidenced by increases in LV end systolic and diastolic volumes, and significant 14 
contractile impairment as evidenced by a marked reduction in ejection fraction. There was also 15 
evidence of LV posterior wall thinning. Heart rates were similar in the two groups (Fig. 3A, B). In 16 
addition increased relaxation time of a gadolinium contrast agent in magnetic resonance imaging 17 
(MRI) of hearts suggested functionally relevant fibrotic remodelling of the myocardium (Fig 3C). 18 
Quantitative (q)PCR analysis of csPLA-Tg myocardium showed that there was reduced 19 
mRNA expression of Myh6 and increases in Myh7, Nppa  and Nppb mRNA consistent with heart 20 
failure (Fig. 4A). This was supported by post-mortem analysis which showed csPLA-Tg hearts were 21 
enlarged at four weeks (Fig 4B,C) whilst mass, based on heart weight relative to tibia length, was 22 
similar between csPLA-Tg and FLctrl mice at two and four weeks (Fig. 4D). Transudative pleural 23 
effusions were evident upon opening the chest cavity in four-week old csPLA-Tg mice symptomatic 24 
of heart failure (Fig. 4E). 25 
Enzyme linked immunosorbent assay (ELISA) of blood plasma identified a substantial 26 
increase in the plasma concentration of cardiac troponin T in four-week csPLA-Tg mice, indicative of 27 
 6 
significant CM damage or death (Fig. 4F). Increases in terminal deoxynucleotidyl transferase dUTP 1 
nick end labeling (TUNEL) positive nuclei indicated cell death occurred (Fig. 4G), though there was 2 
no evidence of caspase 3 cleavage or lamin cleavage, indicators for apoptosis (Fig. 4H), suggesting 3 
necrosis rather than apoptosis was the mode of cell death. 4 
csPLA-Tg myocardium exhibits fibrotic remodelling and an inflammatory senescence 5 
associated secretory phenotype  6 
Inspection of Haemotoxylin and Eosin (H&E) stained tissue sections showed that csPLA-Tg heart 7 
tissue at two weeks was mostly normal, with sporadic regions of mononuclear aggregation in the 8 
myocardial interstitium. At four weeks however csPLA-Tg myocardium was in disarray and 9 
substantial mononuclear infiltration was observed (Fig. 5A). Similarly, picrosirius red staining was 10 
comparable between csPLA-Tg and FLctrl at two weeks, but at four weeks csPLA-Tg myocardium 11 
displayed substantial red staining indicating fibrotic remodelling had occurred (Fig. 5B) supporting 12 
the LGE data observed in the MRI assessment of myocardium. Observation of mononuclear 13 
infiltration in the myocardium suggested that inflammatory cells were activated and present in csPLA-14 
Tg hearts and this was confirmed by immunofluorescence staining of myocardial sections for CD45 15 
(Fig. 3A), which showed increased numbers of CD45+ cells in the myocardium of both two and four 16 
week old mice (Fig. 5C,D). Myocardial inflammation has not previously been reported in models of 17 
LMNA cardiomyopathy, so to test whether this was unique to our model we performed 18 
immunostaining on Lmna-/- myocardium for CD45 and observed no increase in CD45+ cells 19 
compared with wildtype indicating that this was a feature unique to prelamin A accumulation (Fig. 20 
5E). Furthermore, mRNA expression analysis of myocardium for pro-inflammatory cytokines found 21 
that at four weeks Tnf, Icam1, Cxcl1 and Ccl2 were elevated in csPLA-Tg myocardium (Fig. 5F).   22 
Because disruption to the nuclear lamina is associated with premature senescence (28, 29) and 23 
in turn senescence is associated with inflammation via the senescence-associated secretory phenotype 24 
(SASP) (30), we postulated that csPLA-Tg myocardium may display traits of senescence. This was 25 
supported by q-PCR, which showed expression of mRNA for the genes encoding senescence markers 26 
p16 (Cdkn2a) and p21 (Cdkn1a), were upregulated in four-week csPLA-Tg myocardium (Fig 5F). 27 
 7 
Immunohistochemistry for p16 confirmed an increase at the protein level in four week csPLA-Tg 1 
myocardium (Fig. 5G).  In addition, intense senescence-associated β-galactosidase (SA-β-gal) 2 
staining was observed in four-week csPLA-Tg myocardium when compared with FLctrl (Fig 5H).  3 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling was activated 4 
in csPLA-Tg myocardium 5 
NF-κB is a master regulator of inflammation (31). It is also known that prelamin A can activate NF-6 
κB via persistent DNA damage and a non-canonical signalling pathway involving signalling partners 7 
such as IκBα (32). Persistent activation of the DNA damage response is also responsible for activation 8 
of senescence in laminopathies (9). Thus, we hypothesised this might be activated in csPLA-Tg mice. 9 
The p65 subunit of NF-κB is translocated to the nucleus upon activation so to investigate this we 10 
performed quantitative immunofluorescence staining and showed that this was occurring at four 11 
weeks (Fig. 6A,B). To substantiate this finding Western blot indicated elevated expression of p65 at 12 
four weeks but not two weeks (Fig 6C). We then assessed DNA damage signalling by phosphorylated 13 
Histone 2AX (γ-H2AX)—a first responder and activator of DNA damage signalling. We found that γ-14 
H2AX staining as a percentage of total nuclear stain was inconsistent in two week myocardium whilst 15 
in four-week csPLA-Tg myocardium there was a trend towards an increase (P = 0.057) (Fig. 6D,E). 16 
To investigate further we assessed the DNA damage transducer Ataxia Telangiectasia Mutated 17 
(ATM), which can activate NF-κB signalling via IκBα. Western blotting of myocardial lysates from 18 
four-week old mice showed ATM and IκBα were consistently phosphorylated in csPLA-Tg 19 
myocardium (Fig. 6F) Taken together these data infer that activation of inflammatory NF-κB 20 
signalling via ATM is a consequence of prelamin A accumulation in heart. 21 
Disruption to the LINC complex and cytoskeleton was preceded by loss of histone marks in 22 
csPLA-Tg myocardium 23 
Inconsistencies between the activation of NF-κB and the onset of inflammation encouraged us to 24 
explore other pathways consistently affected in two week myocardium. The structural hypothesis of 25 
lamin dysfunction argues that nuclear envelope disruption can lead to increased susceptibility to 26 
 8 
mechanical stress and structural instability of cells (3). Western blotting of LINC complex proteins 1 
and the intermediate filament desmin showed profound changes in expression at four weeks but not at 2 
two weeks (Fig 7A). Transmission electron microscopy (TEM) of csPLA-Tg myocardium showed 3 
that nuclear morphology defects could be observed at four weeks, though not at two weeks (Fig 7B). 4 
Another theory of lamin dysfunction hypothesises that regulation of gene expression is affected by 5 
lamina disruption. TEM images showed a loss of chromocentres and heterochromatin bundles which 6 
did appear to occur at two weeks in csPLA-Tg myocardium (Fig. 8A). We decided therefore to assess 7 
the chromatin changes by investigating methylation of lysine 9 of histone 3 (H3K9me3). We 8 
performed and quantified immunohistochemical staining for H3K9me3 expression and discovered a 9 
profound loss of H3K9me3 in two week csPLA-Tg myocardium (Fig. 8B)). 10 
Prelamin A accumulates in HIV patients undergoing antiretroviral therapy with protease 11 
inhibitors 12 
Because we observed an inflammatory phenotype in the csPLA-Tg model, we postulated this may 13 
also occur in the human setting. Due to the paucity of material we were unable to test this with 14 
CD45+ staining. However, visualisation of the prelamin A stained tissue sample showed regions 15 
containing large clusters of nuclei indicative of leukocyte infiltration, which was not observed to the 16 
same extent in non-prelamin A expressing DCM tissue (Fig. 9A). Subsequently we studied the 17 
literature for inflammatory cardiomyopathies and focussed on HIV associated cardiomyopathy (33). 18 
Because of the association of HIV PIs with the accumulation of prelamin A in other tissues we 19 
hypothesised that prelamin A would be abundant in HIV+ patients on a regime of HIV PIs exhibiting 20 
symptoms of cardiomyopathy as proven by echocardiographic assessment (Table 1). Histological 21 
assessment by H/E and immunohistochemistry for CD3+ and prelamin A confirmed the presence of 22 
inflammation in conjunction with prelamin A expression (Fig. 9B). Indeed, prelamin A 23 
immunohistochemistry showed focal expression of prelamin A in nuclei of CM and non-CM 24 
populations within the hearts of HIV+ patients with a number of CM nuclei showing highly aberrant 25 
morphologies. Western blotting also revealed that abundance of prelamin A was increased in HIV+ 26 
patients compared to a non-failing control (Fig 9C).  Aberrant nuclear morphology and changes in the 27 
 9 
spatial organisation of heterochromatin were also observed at the ultrastructural level in HIV+ 1 
myocardium compared to NF controls (Fig. 9D) and these observations were consistent with the 2 
nuclear morphology defects and loss of heterochromatin bundles observed by TEM in the csPLA-Tg 3 
mice (Fig. 7C, 8A).   4 
Inducible expression of prelamin A in adult hearts causes progressive heart dysfunction, 5 
inflammation and premature death  6 
To this point, our model has tested constitutive accumulation of prelamin A, mostly relevant to 7 
inherited/genetic cardiomyopathies. Because HIV and associated cardiovascular diseases are 8 
predominantly acquired later in life, we wanted to mimic this by testing our model using an inducible 9 
MerCreMer system in adult mice and tracking disease onset by monitoring mice and performing serial 10 
echocardiography (Fig. 10A). We induced mice at 34 ± 3 weeks of age with tamoxifen which led to 11 
nuclear envelope accumulation of prelamin A (Fig. 10B). Median survival for csPLA-Tg mice was 65 12 
days post injection (Fig. 10C). Whilst, body weight remained consistent (Fig 10D), ejection fraction 13 
was significantly attenuated from 6 weeks onwards and left ventricular end systolic volume was 14 
significantly increased at 8 weeks (Fig. 10E). Moreover, histological examination revealed that 15 
similar to constitutive expression of prelamin A hearts were fibrotic and subjected to myocardial 16 
disarray (Fig 11 A, B).  Importantly, CD45+ leukocyte infiltration, indicating inflammation was also 17 
evident consistent with the phenotype observed in patients with acquired HIV cardiomyopathy (Fig. 18 
11C, D). 19 
Discussion 20 
Accumulation of prelamin A occurs in genetic and HIV associated cardiomyopathy 21 
To date the role of prelamin A in the setting of cardiomyopathy has been understudied. Here, we 22 
investigated a cohort of patient samples, for which the primary diagnosis was idiopathic DCM. We 23 
showed consistent prelamin A accumulation in one DCM sample and sporadic accumulation in all 24 
other samples, including non-failing controls. Although sequencing of this one sample could not be 25 
performed, the consistent detection of prelamin A suggested there may be a genetic basis for the 26 
 10 
disease in this patient. Additionally, this accumulation is likely to cause and/or exacerbate 1 
cardiomyopathy as evidenced by our study of a novel csPLA-Tg mouse line where severe cardiac 2 
dysfunction was observed. We also present compelling evidence showing prelamin A accumulation in 3 
HIV associated cardiomyopathy, since all samples tested showed elevated prelamin A abundance, and 4 
nuclear morphology defects. A feature of HIV cardiomyopathy is inflammation and consistent with a 5 
role for prelamin A in this both constitutive and inducible mouse models of prelamin A accumulation 6 
developed extensive myocardial inflammation.  In the constitutive model we also observed 7 
myocardial senescence and mechanistically, we linked the inflammatory response to modulation of 8 
NF-κB signalling, via activation of ATM. However, epigenetic changes may also be more important 9 
when considering early initiating mechanisms. 10 
Prelamin A accumulation causes “Inflammageing” of the myocardium in mice 11 
Though inflammation is known to occur during and after ischaemic events and later in heart failure 12 
(34) it is less commonly described in the progression to DCM. However, HIV associated 13 
cardiomyopathy is strongly associated with an inflammatory response in the myocardium (35, 36). 14 
Recent reports show that HAART exposure in perinatal cases of HIV ultimately benefits heart 15 
function compared with patients from the pre-HAART era (37) for whom opportunistic infections 16 
(38) and potential incorporation and replication of HIV into CMs were problematic (39). 17 
Nevertheless, a decline in cardiac function occurs when compared to the normal population and 18 
HAART therapies may contribute to this. NRTI’s, which prevent replication of HIV, also inhibit 19 
transcription of mitochondrial DNA and have been shown to cause cardiac dysfunction in mice (25, 20 
26). Our study presents evidence that inflammation is the key outcome of prelamin A accumulation in 21 
CMs, and this is also a relatively unique phenotype of HIV associated cardiomyopathy. Though not 22 
subjected to rigorous interrogation of inflammatory pathways, global Zmpste24-/- mouse myocardium 23 
also showed leukocyte infiltration further supporting a role for prelamin A toxicity in driving 24 
inflammation (40). In contrast, inflammation has not been reported in other Lmna mouse models of 25 
cardiomyopathy. Moreover, cardiomyocyte specific overexpression of wildtype lamin A in mice 26 
showed no phenotypic effect or impact on survival implying that processing mechanisms are able to 27 
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cope with an increase in prelamin A concentration (41). In this context, it appears that accumulation 1 
of prelamin A which cannot be processed, is pathogenic. 2 
We provide evidence that the trigger for inflammation is likely linked to myocardial 3 
senescence. Whilst expression of γ-H2AX, the most commonly used marker for DNA damage, was 4 
inconsistent in csPLA-Tg myocardium, ataxia telangiectasia mutated (ATM) which signals down-5 
stream of γ-H2AX, was persistently phosphorylated at four weeks. We observed that p16 and p21 6 
mRNA was increased, along with mRNA of pro-inflammatory cytokines Tnf-α, Icam1, Cxcl1, Ccl2, 7 
suggesting that myocardium in these mice exhibit the SASP. We were able to further substantiate this 8 
by the detection of senescence associated β galactosidase (SA-β-Gal) in csPLA-Tg myocardium. 9 
Furthermore, these data concur with previous work showing that when prelamin A accumulates in 10 
vascular smooth muscle cells activation of the SASP occurs (42). 11 
Early loss of repressive histone marks indicates gene expression pathways are initiators of 12 
pathogenesis 13 
Global Zmpste24-/- mice suffer from systemic inflammation arising from non-canonical ATM-14 
dependent NF-κB signalling (32) and we showed that this pathway was activated locally in csPLA-Tg 15 
hearts at four-weeks making it likely that increases in SASP factors are caused by activation of NF-16 
κB. However, the absence of NF-κB signalling at two weeks suggests that this inflammatory pathway 17 
propagates rather than initiates disease mechanisms. Therefore, we speculated to other mechanisms 18 
for disease genesis. One of these was based on the mechanical hypothesis of lamin dysfunction. We 19 
reasoned that susceptibility to mechanical stress, which is continual and repetitive in the heart, might 20 
lead to structural defects in the nuclear envelope and cytoskeleton. However, in the main these were 21 
not observed until four weeks, meaning this was unlikely. Myh6 and Myh7 mRNA encoding α- and β-22 
MHC respectively did change at 2 weeks and may indicate early changes to myofilament structure 23 
and may also reflect global changes in transcriptional activity as preceding structural defects. 24 
Therefore we speculate epigenetic changes may prime the tissue for disease, since chromatin 25 
displacement and loss of H3K9me3 were observed in two week mouse hearts. The mechanisms 26 
downstream of this remain to be determined but may involve misregulation of the polycomb 27 
 12 
repressive complexes (43), known to control senescent genes such as those encoding p16 and p21 and 1 
potentially induce SASP independently of DNA damage pathways (44).  2 
Study Limitations 3 
Due to difficulties in obtaining human tissue, we do not have the relevant ‘control’ groups i.e. HIV PI 4 
naïve and/or on alternate therapies i.e. NNRTIs, to fully conclude that HIV PIs are the cause of 5 
prelamin A accumulation, though based on current literature it is unlikely that these groups of patients 6 
would experience prelamin A accumulation.  7 
 Our constitutive mouse model was highly malignant and as such does not perhaps faithfully 8 
model the situation in cardiomyopathy, which tends to be more progressive in nature, though the 9 
LMNA cardiomyopathies are amongst the most severe. However our inducible model was far less 10 
severe and represented a more progressive disease and is also relevant to HIV associated 11 
cardiomyopathy which are likely to be propagated by the accumulation of prelamin A where HIV PIs 12 
with high binding affinity to ZMPSTE24 are still being used for treatment. However one key 13 
difference is the model we used relied on mutating the site of ZMPSTE24 cleavage and so does not 14 
fully model the problem in HIV associated cardiomyopathy, where a Zmpste24 Knockout or HIV PI 15 
pharmacological intervention would be interesting for further study. However, despite this our study 16 
shows in a reductionist manner that prelamin A is a toxic mediator of disease in cardiac tissue 17 
indicating that disease is likely to be mediated by the accumulation of prelamin A specifically rather 18 
than any divergent targets or pathways such as the declogging of translocons, the only other known 19 
and recently discovered function of ZMPSTE24 (45-47).  20 
Conclusions 21 
In summary we have identified a novel role for prelamin A in HIV associated and dilated 22 
cardiomyopathies. Accumulation of prelamin A has catastrophic consequences for the integrity of the 23 
myocardium resulting in an “inflammageing” phenotype and subsequent loss of contractility. Whilst 24 
targeting inflammation potentially via ATM activity may prove useful for patients with established 25 
DCM owing to prelamin A accumulation, the immediate translational aspect of this study lies in the 26 
 13 
implications for the treatment of HIV associated cardiomyopathy patients, for whom, a change of 1 
therapy may have a beneficial outcome in the clinic. Elegant biochemistry performed by Robinson 2 
and colleagues provided compelling evidence that HIV PIs bind and block activity of ZMPSTE24 3 
(48). Moreover they were also able to show a rank order of affinity to ZMPSTE24 of HIV PIs 4 
currently available for use- lopinavir > ritonavir > amprenavir > darunavir. Of these, darunavir was 5 
shown not to bind ZMPSTE24 at all, which confirms earlier work (49). Many HIV+ patients suffering 6 
from cardiac symptoms are not currently using darunavir in their HAART regimes (Table 1). 7 
Adjusting HAART regimes to incorporate darunavir and other HIV protease inhibitors with low 8 
affinity to ZPMSTE24 may reduce prelamin A accumulation and provide therapeutic benefit for 9 
patients suffering from symptoms of HIV associated cardiomyopathy. Moreover, many therapeutic 10 
regimes are now beginning to move away from a HIV PI backbone, in favour of non-nucleoside 11 
reverse transcriptase inhibitors (NNRTIs) i.e. rilvipirine, and such an approach should be considered 12 
in patients with cardiac side-effects who are still receiving high doses of HIV PIs. 13 
Materials and Methods 14 
Generation of cardiomyocyte (CM) specific prelamin A transgenic (csPLA-Tg) mice 15 
This mouse model was commissioned from Taconic-Artemis with the aim to devise a transgenic 16 
system to assess the in vivo effects of uncleavable prelamin A overexpression. We performed site 17 
directed mutagenesis of the human LMNA gene at leucine 647 and replaced it with arginine (LMNA-18 
L647R). This corresponds to the cleavage site for ZMPSTE24 and blocks cleavage. The system 19 
involved recombinase mediated cassette exchange (RMCE) of the Rosa26 gene whereby LMNA-20 
L647R cDNA was inserted into an exchange vector containing a neomycin resistance gene, a strong 21 
CAGGS promoter sequence and a STOP cassette flanked by loxP sites. Electroporation into the 22 
embryonic stem (ES) cells of C57BL/6 mice led to site-specific recombination by the recombinases 23 
F3 and FRT. Neomycin resistant clones that had undergone RMCE were selected. After 24 
administration of hormones, superovulated BALB/c females were mated with BALB/c males. 25 
Blastocysts were isolated from the uterus at 3.5 days post coitum (dpc) for microinjection. Blastocysts 26 
 14 
were placed in a drop of DMEM with 15% FCS under mineral oil. A flat tip, piezo actuated 1 
microinjection-pipette with an internal diameter of 12-15 µm was used to inject 10-15 targeted 2 
C57BL/6NTac ES cells into each blastocyst. After recovery, 8 injected blastocysts were transferred to 3 
each uterine horn of 2.5 dpc, pseudopregnant NMRI females. Chimerism was measured in chimeras 4 
(G0) by coat colour contribution of ES cells to the BALB/c host (black/white). Highly chimeric mice 5 
were bred to strain C57BL/6 females. Recombination by mating with mice carrying cre-recombinase 6 
under the control of the myosin light chain 2 ventricular (MLC2v) promoter led to removal of the stop 7 
cassette allowing expression of uncleavable prelamin A in nuclei of CMs of affected offspring. These 8 
mice were called CM specific prelamin A transgenic (csPLA-Tg) mice. They were compared to mice 9 
expressing the transgene but retaining the lox P sites, termed floxed controls (FLctrl). For 10 
investigation of inducible prelamin A expression, breeding was performed with mice expressing cre 11 
recombinase flanked by fragments of the estrogen receptor (MerCreMer) which allowed tamoxifen 12 
inducible expression also under the control of the MLC2v promoter and were termed inducible- 13 
(i)csPLA-Tg. Induction was performed by three once-per-day intra-peritoneal injections of 20 mg/kg 14 
of Tamoxifen dissolved in peanut oil. Genotyping was performed by PCR on ear tissue DNA using 15 
primers designed to detect both the wildtype Rosa26 (377bp) and modified Rosa26 (200bp) loci: 16 
Forward 5’ GTGGATGCTGAGAACAGGC 3’, reverse: 5’ TCCACCTGGTCCTCATGC 3’ and also 17 
for the expression of Cre recombinase: Forward: TGCCAGGATCAGGGTTAA, reverse 5’ 18 
CCCGGCAAAACAGGTAGTTA 3’. cycling parameters were initial denaturation 95°C 1 min, 19 
denaturation 95°C 30 seconds*, annealing 60°C 30 seconds*, extension 72° 1 min*, final extension 20 
72°C 10 min, cooled to 4°C indefinitely. (*repeated for 35 cycles) All csPLA-Tg mice used in the 21 
study were heterozygous for the transgene and generated on a C57Bl6 background. Mice were kept in 22 
individually ventilated cages (IVC) at the biological services unit (BSU) at the Maurice Wohl Clinical 23 
Neuroscience Institute, Kings College London, fed a standard chow diet and kept on a 12 hour 24 
light/dark cycle.  Male and female mice were used in this study 25 
 26 
 27 
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Lmna-/- mice 1 
A heterozygous breeding colony of mice with a null allele of Lmna (50) was established to obtain 2 
Lmna−/−, Lmna−/+ and Lmna+/+ (wild-type), Mice were genotyped by PCR on genomic tail DNA using 3 
the Manual ArchivePure DNA Purification Kit (5Prime, Gaithersburg, MD, USA) using the following 4 
primers: Forward: 5’ CGATGAAGAGGGAAAGTTCG 3’, Mutant-specific reverse: 5 
5′GCCGAATATCATGGTGGAAA 3’, Wild-type-specific reverse: 5′ 6 
CCATGGACTGGTCCTGAAGT 3′. Cycling parameters were the same as for csPLA-Tg genotyping. 7 
PCR produced a 750 bp amplicon from the mutated allele and a 520 bp amplicon from wild-type. 8 
Mice were housed at the BSU at New Hunts House, King’s College London, fed a standard chow diet 9 
and kept on a 12 hour light/dark cycle. 10 
Murine echocardiography 11 
Echocardiography was performed using a Vevo 2100 imaging system with a 30 MHz linear 12 
transducer specially designed for small animal studies (VisualSonics, USA). Echocardiography was 13 
performed with 5% isofluorane fast induction of anaesthesia followed by maintenance of 1-1.5% 14 
isoflurane anaesthesia for 4 week old mice and 2.5% isofluorane for 2 week old mice, which was 15 
vaporized in 100% oxygen delivered at 1.5-2 liters/min. Heart rate was kept at ~400-450 beats per 16 
minute while respiratory rate was ~100 breaths per minute. Body temperature was ~36.5±1°C. 17 
Murine cardiac Magnetic Resonance Imaging (MRI)  18 
Cardiac MRI was performed at the James Black Centre, King’s College London on a 7 Tesla (T) 19 
horizontal MR scanner (Varian Inc., Palo Alto, CA) with mice in the prone position. The gradient coil 20 
had an inner diameter of 12 cm; the gradient strength was 1000 mT/m (100 G/cm), and rise-time was 21 
120 ms. A quadrature transmit/receive coil (RAPID Biomedical GmbH, Germany) with an internal 22 
diameter of 39 mm was used. Anesthesia was maintained with 1.5% isoflurane/98.5% oxygen and 23 
body temperature was maintained at 37°C using a warm air fan (SA Instruments, Stony Brook, NY). 24 
The ECG was monitored by means of two metallic needles placed subcutaneously in the front paws. 25 
 16 
A pressure-transducer for respiratory gating was placed on the animal abdomen. To synchronize data 1 
acquisition with the ECG and to compensate for respiratory motion, simultaneous ECG triggering and 2 
respiration gating (SA Instruments) were applied. Functional and volumetric parameters were 3 
achieved following a multi slice Cine-FLASH acquisition (51). These parameters were used: FOV = 4 
25 x 25 mm2, slide thickness = 1 mm, matrix size = 128 x 128, 9 to 10 frames/cycle, 9 slices, flip 5 
angle =40°, cardiac cycle = 120 ± 30 ms, averages = 3, acquisition time ≈ 8 min. Functional and 6 
volumetric parameters were calculated from cine-FLASH images and areas of contrast-enhancement 7 
were calculated using a semi-automated in-house developed computer software program (King's 8 
College London, ClinicalVolumes). 9 
For detection of myocardial ‘scarring’ by T1 mapping (52), anaesthetised mice were subject 10 
to MR imaging before and 25 min after intraperitoneal (i.p.) administration of 0.75 mmol/kg of 11 
gadofosveset trisodium (Ablavar®, Lantheus Medical Imaging, North Billerica, MA), a gadolinium-12 
based contrast agent. An ECG triggered, single slice, Look-Locker acquisition was used for T1 13 
mapping and to measure R1 values of the myocardium. The slice was selected in the middle of the 14 
heart. Imaging parameters included FOV = 25 x 25 mm2, slice thickness = 1 mm, matrix size = 128 x 15 
128, 3 phases/cycle, total of 30 phases, 1 slice, flip angle = 10°, TR. 2700 ms, TReff ≈ 40 ms 16 
((cardiac cycle)/(3 phase/cycle)), TE = 2 ms, cardiac cycle = 120 ± 20 ms, number of averages = 1, 17 
acquisition time ≈ 13 min. T1-weighted sequences were analysed to assess the R1 values of the 18 
myocardium. 19 
Look-Locker T1 mapping resulted in 30 images (3 per cardiac cycle) from which R1 values 20 
of blood, infarcted, remote and healthy myocardium were calculated using an exponential 3 parameter 21 
fit (A-B*exp (-TI/T1*)) with subsequent T1 correction (OriginLab Corporation, Wellesley, USA). 22 
Transmission Electron Microscopy (TEM) 23 
Mice were injected intraperitoneally with heparin (5000 u/kg body weight). This was followed by 24 
intraperitoneal injection of 50mg/kg body weight of sodium pentobarbital to induce terminal 25 
anaesthesia. The chest cavity was opened and secured with a hemostat. The LV was injected with a 26 
needle connected via a pump to a reservoir of pre-wash buffer. Flow rate of the pump was adjusted as 27 
 17 
to perfuse mouse heart at a pressure between 90-100 mmHg with pre-wash buffer. Pre-wash buffer 1 
was a standard physiological tyrode solution containing 10mM BDM to arrest the heart in diastole and 2 
2.5% PVP to replace the protein content of blood, thereby maintaining colloidal pressure and 3 
preventing haemorrhage at vascular sites in the heart. Following prewash, the hearts were perfused 4 
with fixative solution containing 2% Glutaraldehyde and 2% Paraformaldehyde until 20ml of fixative 5 
had been perfused. Hearts were dissected and the mid LV was isolated and cut for further processing. 6 
Samples were dehydrated through a graded series of ethanol washes and embedded in epoxy resin. 7 
Semi-thin sections (0.2 μm) were stained with toluidine blue for light microscopy examinations and 8 
were used to guide sampling for TEM studies. Thin sections (0.09 μm) were collected on 150-mesh 9 
copper grids and double stained with uranyl acetate and lead citrate for examination under TEM 10 
(H7650, Hitachi, Tokyo, Japan).  11 
Human HIV+ samples were fixed in 2% glutaraldehyde in a 0.1 M phosphate buffer, at pH 12 
7.3, post fixed in osmium tetroxide and processed following a standard schedule for embedding in 13 
Epon resin. Semi-thin sections were stained either with azur-II or basic fuchsin solutions and mounted 14 
with permount medium. Ultrathin sections (70-80) were stained with uranyl acetate and lead 15 
hydroxyde. A Jeol 1400 plus TEM was used for observation and photographic analysis. 16 
Human Echocardiography 17 
Echocardiograophy was performed single centre using a Philips epic ultrasound machine. 18 
Echocardiographic parameters were determined according to established criteria (53). In particular, 19 
ejection fraction was calculated in the apical 4 and 2-chamber views from three separate cardiac 20 
cycles using the modified Simpson's method and left ventricular end-diastolic diameter was measured 21 
in long-axis and short-axis view. 22 
Statistics 23 
All in vivo and ex vivo data of csPLA-Tg versus FLctrl mice were analysed using the a two-way 24 
analysis of variance without repeated measures with Sidak’s post hoc test for direct comparison of 25 
age-matched groups. Student’s unpaired T-test was applied when only four week old mice were 26 
 18 
compared. Where unequal variances were observed Welch’s correction was applied. For the analyses 1 
of body weights over time and serial echocardiography, two-way analysis of variance with repeated 2 
measures was selected with Sidak’s post hoc test for comparison of groups at specific time points of 3 
the series. Kaplan-Meier survival curves were assessed by the log-rank Cox-Mantel test. Values were 4 
expressed as means ± the standard deviation (SD). A p value of <0.05 was considered significant. 5 
Tests were performed in Excel (Microsoft) or Prism (GraphPad). 6 
Study approval  7 
This study complies with the declaration of Helsinki. Human DCM specimens were obtained from the 8 
Sydney Heart Bank (Hospital Research Ethical Committee approval #H03/118; University of Sydney 9 
ethical approval #12146) and from Papworth tissue bank in Cambridge, UK and used in accordance 10 
with ethical guidelines of King’s College London (REC reference 13/LO/1950) and the current UK 11 
law. Studies involving HIV associated cardiomyopathy patient endomyocardial biopsies were 12 
approved by the Ethics Committee of La Sapienza University Rome, and performed because despite 13 
good control of HIV infection patients were experiencing progressive cardiomyopathy. All patients 14 
gave informed consent. All animal procedures were performed in accordance with the Guidance on 15 
the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office).  16 
Detailed accounts of other methods used in this study can be found in the online supplement to this 17 
article.  18 
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Tables 1 
Table 1. Clinical characteristics and antiretroviral treatment regime of five patients with HIV-2 
associated cardiomyopathy 3 
HIV+ Patient ID Age Sex 
Time under 
retroviral therapy, 
years 
Echocardiography Data 
LVEDD*, mm LVEF†, % 
Pt1 35 M 10‡ 65 29 
Pt2 56 M 8§ 56 40 
Pt3 52 M 9|| 48 43 
Pt4 45 M 8# 62 38 
Pt5 45 F 9** 68 35 
Normal Values <56 ≥50 
* LVEDD=Left ventricular end-diastolic diameter 4 
† LVEF= Left ventricular ejection fraction 5 
‡= Emcitrabine/Tenofovir, Atazanavir, Ritonavir,  6 
§=Emcitrabine/Tenofovir, Lopinavir/Ritonavir, Rivotril 7 
||= Atazanavir, Norvir, Abacavir/Lamivudin 8 
#= Abacavir/Lamivudine, Efavirenz, Atazanavir 9 
** Ritonavir, Rivotril, Lamivudine, Zidovudine, Fosamprenavir 10 
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Figure 1. Prelamin A accumulated in a heart of a patient with Dilated Cardiomyopathy. 
(DCM). A. Confocal micrographs of human heart sections from DCM patients and non-failing 
(NF) controls subjected to immunofluorescence staining to detect prelamin A (green), myomesin
(red) and DAPI (blue). Arrows point to prelamin A positive CM nuclei, many of which exhibit 
nuclear morphology defects. B. the number of nuclei which stained positively for prelamin A 
were quantified as a percentage of CM nuclei for non-failing (blue circles, N=10 non-failing 
donor samples) and DCM (red squares, N=21 samples from explanted DCM hearts) myocardial 
sections (means ± SDs). Scale = 10 μm. C. Western blotting did not detect prelamin A in a 
selection of DCM patient samples. There was not enough sample remaining from DCM05 to run 
on a western blot. 
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Figure 2. Targeted transgenesis of prelamin A led to nuclear accumulation in CMs and resulted 
in premature death in mice. A. Schematic representation showing the site of prelamin A (LMNA-
L647R) cDNA insertion and the modifications required for conditional expression. B. Western 
blotting for prelamin A showing expression was restricted to heart tissue C. Confocal micrographs of 
myocardium stained for prelamin A showing nuclear rim localisation in csPLA-Tg hearts. Scale = 10 
μm. C. Growth curves showing that csPLA-Tg mice stop growing after 30 days. N= 3 males/group. 
Two-way ANOVA with repeated measures with Sidak’s post-hoc test for multiple comparisons was 
perfoprmed. *P<0.05, ***P<0.001. D. Kaplan-Meier survival analysis showing that csPLA-Tg male 
and female mice exhibited attenuated survival compared to FLctrl counterparts. N= 7 FLctrl males, 8 
FLctrl females, 9 csPLA-Tg males, 8 csPLA-Tg females. Log-rank Mantel-Cox test was performed. 
P<0.0001
2 weeks 4 weeks
0.0
0.2
0.4
0.6
0.8
1.0
L
V
P
W
;d
 (
m
m
) *
2 weeks 4 weeks
0.0
0.2
0.4
0.6
0.8
IV
S
;d
 (
m
m
)
0
20
40
60
80
L
V
E
D
V
(
l)
P=0.054
0
20
40
60
80
L
V
E
S
V
 (

l)
****
0
20
40
60
80
E
je
c
ti
o
n
 f
ra
c
ti
o
n
 (
%
) ****
0
2 0 0
4 0 0
6 0 0
8 0 0
H
e
a
rt
 r
a
te
 (
b
p
m
)
F L c trl
c s P L A
C
2
 w
e
e
k
s
4
 w
e
e
k
s
FLctrl csPLA-Tg
E
n
d
-d
ia
s
to
le
E
n
d
-s
y
s
to
le
csPLA-TgFLctrlA
F L c tr l c s P L A -T g
0
20
40
60
80
E
je
c
ti
o
n
 f
ra
c
ti
o
n
 (
%
) * * * *
F L c tr l c s P L A -T g
0
20
40
60
L
V
E
D
V
(
l)
* * *
F L c tr l c s P L A -T g
0
10
20
30
40
50
L
V
E
S
V
 (

l)
* * * *
FLctrl csPLA-Tg
30
40
50
60
70
80
M
a
s
s
 (
g
)
B
F L c tr l c s P L A -T g
1 .2
1 .4
1 .6
1 .8
2 .0
2 .2
2 .4
R
1
 (
s
e
c
-1
)
* *
Figure 3. Cardiac function was attenuated in four week old csPLA-Tg mice. A. Representative 
images of echocardiographs and corresponding graphs of analysis performed on movies acquired 
in B-mode showing severely compromised cardiac function in four-week old mice N=12/group (6 
females, 6 males) except csPLA-Tg 2 weeks which was N= 9 (7 females, 2 males). Values are 
means ± SDs, Two way ANVOA no repeated measures was performed with Sidak’s post hoc test 
for multiple comparisons. *P<0.05, ***P<0.001, ****P<0.0001 B. Representative cardiac MRI 
images of myocardium in end systole and end diastole and corresponding graphs displaying a 
decrease in ejection fraction alongside increases in left ventricle end diastolic (LVEDV) and 
systolic volume (LVESV). Mass was statistically unchanged but with increased variation and 
concurs with post-mortem heart weight measurements. C. Increased relaxation time (R1) of 
gadolinium contrast in four week csPLA-Tg myocardium indicative of fibrosis remodelling. N= 6 
males/group. Values are means ± SDs, Students two-tailed T-test was performed. **P<0.01, 
***P<0.001, ****P<0.0001. IVS;d = Intraventricular septal thickness in diastole, LVPW;d = Left 
ventricle posterior wall thickness in diastole.
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Figure 4. csPLA-Tg mice displayed signs of heart failure and necrotic cell death  A. Foetal gene 
expression is dysregulated in csPLA-Tg hearts at four weeks indicating heart failure N=3 females/group. 
Values are means ± SDs. Two-Way ANVOA no repeated measures was performed with Sidak’s post hoc 
Test for multiple comparisons, *P<0.05. B. low magnification micrographs showing cross-sectional view 
of the heart stained with H&E showing four-week csPLA-Tg mice possessed dilated cardiac chambers. 
Scale = 2 mm. C. Photographs showing csPLA-Tg appeared enlarged at four weeks. Scale = 5mm. D. No 
significant difference in heart weight to tibia length ratio was observed. Values are means ± SDs. 
N=3/group. E. Dissection of chest cavities showing transudative pleural effusions in csPLA-Tg mice. F.
Blood plasma subjected to ELISA showed elevated levels of circulating cardiac TNT indicative of cardiac 
damage in four week old mice. N= 3 females/group. Values are means ± SDs. Two-Way ANOVA no 
repeated measures with Sidak’s post hoc test for multiple comparisons was performed. *P<0.05 G.
TUNEL staining was performed on four week csPLA-Tg heart sections and image quantification showed 
a significant increase in TUNEL positive nuclei in csPLA-Tg heart sections at four weeks. N= 3 
females/group. Values are means ± SDs. Student’s two-tailed T-test was perfromed. **P<0.01. H. Western 
blotting showed that cleavage of caspase 3 and lamins A/C, which occurs at ~37 kDa, which occur during 
apoptosis, did not occur in four week csPLA-Tg myocardium.
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Figure 5. Fibrotic remodelling of csPLA-Tg myocardium occurred in tandem with inflammation 
and senescence A. Light micrographs showing myocardial disarray in four week csPLA-Tg
myocardium stained with Haematoxylin and Eosin. Scale = 30μm. B. Light micrographs showing 
Picrosirius red stained myocardium to indicate fibrosis in four week csPLA-Tg myocardium shown by 
excessive red staining. Scale = 30μm. C & D. Quantitative fluorescence immunostaining for CD45 
shows presence of CD45+ cells in two and four-week csPLA-Tg myocardium. Scale = 10 μm. Values 
are means ± SDs. N=3 females/group. Two-way ANOVA with Sidak’s post hoc test for multiple 
comparisons was performed. **P<0.01 E. CD45+ immunostaining of Lmna-/-myocardium showed no 
evidence of infiltration by CD45+ leukocyte populations. F. qPCR showing the cytokine profile of 
csPLA-Tg myocardial mRNA. N=4 females/group. G. Immunohistochemical staining showing 
expression of p16 in four week csPLA-Tg myocardium. H. Senescence associated β galactosidase was 
expressed in four week csPLA-Tg myocardium. 
p65 Myomesin DAPI
2
 w
e
e
k
s
4
 w
e
e
k
s
FLctrl csPLA-Tg
A D
2
 w
e
e
k
s
FLctrl
4
 w
e
e
k
s
p-H2AX Myomesin DAPI
csPLA-Tg
p-ATM
Total-IκBα
p-IκBα
GAPDH
p65
0
1
2
3
*
p
-A
T
M
/T
o
ta
l-
A
T
M
0.0
0.2
0.4
0.6
0.8
1.0
p
-I

B

T
o
ta
l 
I
B

**
0
1
2
3
*
N
F
-
B
/G
A
P
D
H
F
2  w e e ks 4  w e e ks
0
5
10
15
20
25
%
 p
6
5
 p
o
s
ti
v
e
 n
u
c
le
i
*
2  w e e ks 4  w e e ks
0
5
10
15
%
H
2
A
X P = 0 .0 5 7
p65
GAPDH
2 weeks 4 weeks
Total-ATM
37kDa
50kDa
50kDa
250kDa
250kDa
4 weeks
FLctrl csPLA-Tg
B C E
Figure 6. NF-κB signalling was activated in four week csPLA-Tg CMs and mediated by persistent 
DNA damage. A. Subcellular localisation of p65 subunit of NF-κB in csPLA-Tg myocardium, 
highlighted by white arrows B. quantification of p65 micrographs showing increases in the number of 
nuclei expressing p65 for two- and four-week hearts counted as a percentage of total nuclei. N=3 
females/group. Values are means ± SDs, Two-way ANOVA no repeated measures with Sidak’s test for 
multiple comparisons was performed C. Western blot showing increase of NF-κB sub-unit p65 in four 
week csPLA-Tg myocardium. D. Confocal micrographs of fluorescence immunostaining showing DNA 
damage marker γ-H2AX (white arrows). E. Quantification of γ-H2AX micrographs. N=3 
females/group. Values are means ± SDs, Two-way ANOVA no repeated measures with Sidak’s post hoc 
test for multiple comparisons was performed.  D. Western blots of four week myocardial lysates 
showing phosphorylation status of ATM and IκBα and E. graphs showing corresponding densitometry 
analyses. Scale = 10 μm. Values are means ± SDs. N=3 females/group. Unpaired two-tailed T-test was 
performed. *P<0.05 **P<0.001.
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Figure 7. Prelamin A accumulation led to disorganisation of molecular structure at four weeks and 
loss of chromatin and histone marks at two weeks. A & B. Western blot analysis showing the protein 
expression changes occurring at four weeks in structural proteins of the nuclear envelope-lamin A/C, 
emerin, SUN2, nesprin 2, and also the cytoskeleton-desmin, with corresponding semi-quantitative 
densitometry analysis. N=3 females/group. Values are means ± SDs. Unpaired two tailed T-test was 
performed on age-matched groups. Welch’s correction was applied to data for lamin A, lamin C, emerin, 
SUN2 and nesprin2 at four weeks. *P<0.05 **P<0.01 ***P<0.001. C. Electron micrographs showing 
nuclear shape and size changes in csPLA-Tg myocardium, red arrows point to regions of nuclear in-
folding characteristic of nuclear morphology defects. Scale = 1 µm.
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Figure 8. Prelamin A accumulation resulted in loss of heterochromatin and H3K9me3 
repressive histone marks in the myocardium of 2 week old mice A. Representative 
electron micrographs show heterochromatin displacement and loss of chromocentres. 
Scale = 500 nm. B. Quantitative immunohistochemistry showed a profound loss of 
H3K9me3 staining as a percentage of total Haemotoxylin stain in two week csPLA
myocardium. Scale = 30 μm. Values are mean ± SD. N=3 females/group. Two-way 
ANOVA no repeated measures with Sidak’s test for multiple comparisons was performed.* 
P<0.05.
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Figure 9. Prelamin A accumulated in hearts of patients with HIV-associated 
cardiomyopathy under retroviral therapy A. The DCM patient sample in which prelamin A 
accumulated showed profound mononuclear infiltration unlike other DCM samples. Scale = 40 
μm. B. H&E and CD3+ immunohistochemistry showing inflammation in HIV+ myocardium 
consistent with the csPLA-Tg model. Scale = 30μm. C. Immunohistochemistry showing focal 
prelamin A accumulation in CM nuclei (black arrows) and non-CM populations (green arrows) 
of HIV+ myocardium supported by Western blotting, which detected accumulation of prelamin
A in hearts of HIV patients. D. Electron micrographs showing nuclear morphology defects in 
HIV+ myocardium (red arrow, scale = 3 μm) and nuclear pore complexes surrounded by evenly 
spread heterochromatin in non-diseased myocardium (large white arrows) and heterochromatin 
displacement in HIV+ myocardium (small white arrows). Scale = 1 μm. N= Nucleus, L=Lipid 
bodies. 
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Figure 10. Induction of prelamin A expression in adulthood leads to a progressive and 
fatal decline in cardiac function in inducible (i) csPLA-Tg mice. A. Schematic showing 
the protocol for assessing the effect of prelamin A acquired in adult mouse myocardium via 
utilisation of a tamoxifen inducible MerCreMer promoter. B. Immunofluorescence staining 
of heart sections showing the expression of prelamin A in cardiomyocytes of icsPLA-Tg 
mice. Scale = 20µm. C. Kaplan-Meier survival analysis showing that csPLA-Tg male and 
female mice died early compared to FLctrl counterparts, log-rank Mantel-Cox P<0.0001. 
N= D. Body weights remained constant during the course of the protocol. E. Cardiac 
function declined progressively over the course of the protocol. Values are mean ± SD. N = 
9- 8 males and 1 female/group. Two-way ANOVA with repeated measures and Sidak’s test 
for multiple comparisons was performed. ****P<0.0001. F. H&E and picrosirius red 
staining showed myocardial disarray and fibrosis respectively. Scale = 30µm.
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Figure 11. Induction of prelamin A in mouse hearts induces cardiac remodelling and 
inflammation. A. Haemotoxylin and Eosin and B. Picrosirius red staining showed 
myocardial disarray and fibrosis respectively. C. Immunoflourescence micrographs showing 
CD45+ cells were evident in icsPLA-Tg myocardium. Scales = 30µm D. Quantification of 
CD45+ cells showing an increase in leukocyte population in icsPLA-Tg myocardium. 
Values are mean ± SD N= 4 males/group. Unpaired student’s T-test was performed. 
***P<0.001.
Summary Figure.Schematic showing molecular and phenotypic implications of prelamin A1
accumulation in the heart. In a normally functioning heart prelamin A is cleaved by ZMPSTE24 2
leading to laminA insertion in the nuclear lamina. Prelamin A accumulation may occur by mutations 3
in LMNAand ZMPSTE24genes, and also by inhibition of ZMPSTE24 by HIV protease inhibitors. In 4
this setting prelamin Aaccumulation is likely to contribute to the development of inflammatory 5
cardiomyopathy. In the case of HIV PI inhibitonof ZMPSTE24, switichingtreatmentsto the recently 6
non-nucleoside reverse transcriptase inhibitors (NNRTI’s) such asthe recently developed rilvipirine7
and where necessary, selectingHIV PIs with low-or no affinity to ZMPSTE24 may prove beneficial.8
